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FDA Approved Pediatric Antihypertensive Agents
Ashish Doshi
When choosing a long-term antihypertensive agent in a patient, several factors should
be considered: Indications or contraindications with respect to co-morbid conditions, side effect
profile, availability of liquid preparations, dosing interval, and medication cost and generic
availability. Knowledge of which agents are FDA-approved and have undergone trials in
children aids in safe prescribing, but should not prevent one from prescribing an agent not FDAapproved in children. This chapter will review major medication classes, mechanism of action,
representative agents including those approved in children, common or important side effects,
contraindications, and beneficial populations.
Diuretics
In adults, diuretics have been proven to be as effective as ACE inhibitors or calciumchannel blockers in preventing fatal coronary heart disease or nonfatal myocardial infarction,
and perhaps more effective in decreasing blood pressure.1 Thiazide diuretics are one of four
classes of antihypertensives recommended as first-line therapy for hypertension in adults, the
other classes being ACE inhibitors, ARBs, and calcium channel blockers.2 Thiazide diuretics
acutely decrease blood pressure by blocking the sodium-chloride symporter in the distal tubule,
thus preventing salt and water reabsorption and promoting natriuresis and diuresis. Loop
diuretics interfere with the sodium-potassium-chloride cotransporter in the thick ascending limb
of the loop of Henle, thus causing natriuresis and diuresis. The long-term antihypertensive
mechanism of diuretics is less well-understood. Of the diuretics, only hydrochlorothiazide is
FDA-approved in children.3 Other diuretics with pediatric experience include chlorthalidone and
furosemide. Furosemide is FDA-approved for the treatment of edema but can be used as addon therapy for hypertension. Chlorthalidone can precipitate azotemia and therefore should be
used with caution in patients with renal disease. Spironolactone, triamterene, and amiloride are
potassium-sparing diuretics with pediatric experience. For all diuretics, electrolytes should be

monitored periodically, particularly for potassium-sparing diuretics, which can cause
hyperkalemia, especially when used in conjunction with an ACE inhibitor or ARB.
ACE inhibitors and ARBs
ACE inhibitors are the most-commonly prescribed agents for pediatric hypertension.4
ACE inhibitors are direct antogonists of angiotensin-converting enzyme, thus reducing the
conversion of angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor with the
greatest vasoconstrictive action on the efferent arteriole versus the afferent arteriole.
Additionally, it stimulates secretion of aldosterone from the zona glomerulosa cells of the
adrenal glands and induces release of vasopressin from the pituitary; ACE inhibitors therefore
decrease blood pressure through a number of mechanisms. ACE inhibitors can be
renoprotective in patients with diabetes.5 Benazepril, enalapril, fosinopril, and lisinopril are all
FDA-approved in children over 6 years of age with creatinine clearance over 30 mL/min per
1.73 m2.3 Without the action of angiotensin II the afferent arteriole of the glomerulus becomes
more constricted than the efferent arteriole (or one could say the efferent arteriole becomes
more dilated as there is no antiotensin II to cause efferent arteriole vasoconstriction). This
causes decreased glomerular pressure and in low-volume states such as dehydration or
ineffective circulating volume (cardio-renal/hepato-renal syndromes) results in acute decreased
glomerular filtration. Therefore, adequate intravascular volume must be maintained during ACE
inhibitor therapy.6,7 Captopril and quinapril also have pediatric experience. Electrolytes and
renal function should be monitored periodically as hyperkalemia and azotemia are potential
risks. Cough and angioedema are other fairly common side effects: cough reported in up to
12% of patients; angioedema -1 case per 1000 (0.1%) with captopril and enalapril, 1 case per
200 (0.5%) with lisinopril.8 Females of childbearing age must have reliable contraception, as
ACE inhibitors are teratogenic.
Angiotensin receptor blockers are similar to ACE inhibitors in their indications. They
block the angiotensin II receptor, preventing angiotensin II from causing vasoconstriction or

release of vasopressin from the pituitary. The main reason for using an ARB over an ACE
inhibitor is due to the decreased side effect profile (less incidence of cough and angioedema,
though hyperkalemia, azotemia, and teratogenicity remain risks). In theory, because the
reduction in the amount of circulating angiotensin II due to ACE inhibitors is dose-dependent,
combination therapy with an ACE inhibitor and an ARB may be more beneficial than using a
single agent alone. However, combination therapy has not been found to provide greater
benefit and at least in the diabetic population has been shown to increase the risk of
hyperkalemia and acute kidney injury.9 Irbesartan, losartan, and candesartan are all FDAapproved ARBs in children over 6 years of age with creatinine clearance over 30 mL/min per
1.73 m2.3
Beta blockers
Beta blockers antagonize the beta adrenergic receptor. Cardioselective beta blockers
inhibit beta-1 receptors in the heart and kidney, decreasing inotropy and chronotropy as well as
renin release. Non-cardioselective beta blockers inhibit both beta-1 receptors as well as beta-2
receptors. Propranolol is the only FDA-approved beta-blocker in children.3 As a noncardioselective agent, its use is contraindicated in patients with asthma. Cardioselective agents
with pediatric experience include metoprolol and atenolol. Labetalol is a combined alpha- and
non-cardioselective beta-blocker and as such should also not be used in patients with asthma.
The additional peripheral alpha-1 blockade relaxes vascular smooth muscle, aiding in the
antihypertensive effect. For all of these medications, bradycardia is the limiting factor in titrating
up the dose. In addition, the blunting of appropriate tachycardia may reduce athletic
performance. Beta-blockers should not be used in insulin-dependent diabetics as beta-2
activation stimulates hepatic glycogenolysis, helping to keep blood sugar levels stable.
Calcium channel blockers
Amlodipine is the only FDA-approved calcium channel blocker in children.3 Felodipine,
isradipine, and extended-release nifedipine also have pediatric experience. Calcium channel

blockers inhibit L-type calcium channels in the heart and in vascular smooth muscle. They
reduce blood pressure by decreasing myocardial chronotropy and inotropy as well as causing
arterial and arteriolar dilation. In all calcium-channel blockers, reflex tachycardia can result from
peripheral vasodilation.
Central alpha agonists
Clonidine is FDA-approved in children over 12 years.3 It acts as an agonist on central
alpha-2 receptors in the vasomotor center of the brainstem, thus decreasing norepinephrine
release and decreasing vascular tone. In addition to the oral preparation, a transdermal patch
preparation is available. Patients should be monitored for anti-cholinergic side effects such as
dry mouth or sedation. Suddenly discontinuing the agent can result in severe rebound
hypertension.
Peripheral alpha antagonists
Doxazosin, prazosin, and terazosin have all been studied in children, though none of
them are FDA-approved. These agents inhibit binding of norepinephrine to alpha-1 adrenergic
receptors on vascular smooth muscle, thus causing vasodilation. These agents are infrequently
used, mainly due to available alternative agents with more pediatric experience. In adults, the
large ALLHAT study showed that doxazosin was less effective than diuretics at reducing blood
pressure, and the doxazosin study arm was stopped due to an increased rate of cardiovascular
disease and congestive heart failure.1 Peripheral alpha antagonists can sometimes cause
hypotension or syncope when starting therapy.
Direct vasodilators
Hydralazine and minoxidil are both FDA-approved in children.3 Hydralazine activates
potassium channels in vascular smooth muscle cells, thus hyperpolarizing them and preventing
the increase in intracellular calcium necessary for smooth muscle contraction.10 Because of the
direct vasodilation, reflex tachycardia and fluid retention (from increased venous capacitance)
can be seen. Minoxidil’s mechanism of action is not well-understood but is thought to largely be

due to activation of potassium channels10 with a mechanism similar to that of hydralazine.
Minoxidil is well-known as a topical preparation to treat androgenetic alopecia,11 so one of the
side effects of oral minoxidil is hypertrichosis. Hypertrichosis usually resolves 1-6 months after
stopping therapy.
Medication

Dose

Comments

* = FDA approved in
pediatric population.
<6 mos: 2-4mg/kg/day
>6 mos 1-2 mg/kg/day;
Hydrochlorothiazide*

usually twice daily;
Max dosing >6mos-2 years= 37.5mg day
>2 years= 100mg/day

Lisinopril*

Enalapril*

0.7mg/kg/day; usually once daily;
Max dosing 0.6mg/kg/day up to 40mg/day
0.8mg/kg/day; usually twice daily;
Max dosing 0.6mg/kg/day up to 40mg/day
<6 years: 0.2 mg/kg/day
>6 years <50kg: 4-8 mg daily

Candesartan*

>6 years >50kg: 8-16 mg daily
usually once daily;
Max dosing 32 mg/day

Losartan*

0.7 mg/kg/day; usually once daily ;
Max dosing 1.4 mg/kg/day up to 100 mg/day

Valsartan*

1.3 mg/kg/day; usually once daily;
Max dosing 2.7 mg/kg/day up to 160mg/day

Propranolol*

1-2 mg/kg/day; usually twice daily;
Max dosing 8 mg/kg/day up to 640 mg/day
1-3 mg/kg/day; usually twice daily;

Labetalol

Max dosing 10-40 mg/kg/day up to 1200
mg/day

Exposure to
valsartan in
suspension is 1.6
times greater than
the tablet form.

Medication

Dose

Comments

* = FDA approved in
pediatric population.
Amlodipine*

2.5 -10 mg/day; once daily dosing;
Max dosing 10mg

Nifedipine

0.1-0.2 mg/kg/dose; usually given q. 4 hours;
Max dosing 0.5 mg/kg/dose

Clonidine*

Can cause abrupt
blood pressure
reduction to
hypotensive levels.

0.05mg once daily; usually give TID;
Max dosing 0.6 mg/day

Transdermal Clonidine*
Doxazosin

Applied every 7 days
1 mg once daily; usually give once daily;
Max dosing 4mg/day

Hydralazine*

0.75mg/kg/day; usually in 4 divide doses;
Max dosing 7.5mg/kg or 200mg daily

Minoxidil*

0.2mg/kg/day; usually once daily;
Max dosing 50mg/day
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